MUSK and myasthenia gravis: The efficacy of efgartigimod in non-exacerbation MuSK-Ab-positive patients with MG has been demonstrated in a phase III clinical trial, with all three patients showing positive treatment outcomes as responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale.